Adsorptive granulocyte and monocyte apheresis: A potentially relevant therapeutic option for COVID-19

Int J Infect Dis. 2020 Oct;99:1-2. doi: 10.1016/j.ijid.2020.07.025. Epub 2020 Jul 25.

Abstract

The overproduction of proinflammatory cytokines and subsequent thromboembolism are major problems of coronavirus disease 2019 (COVID-19). Adsorptive granulocyte and monocyte apheresis (GMA), used for ulcerative colitis, is an extracorporeal therapy designed to remove activated myeloid lineage cells. Previous studies have demonstrated that GMA decreases proinflammatory cytokines and neutrophil-platelet aggregates. The effect of GMA on COVID-19 in a patient with ulcerative colitis was recently reported. The modes of action of GMA together with the findings of this case report indicate that GMA could be a relevant treatment option for COVID-19.

Keywords: Adsorptive granulocyte and monocyte apheresis; COVID-19; SARS-CoV-2.

MeSH terms

  • Adsorption
  • Adult
  • Betacoronavirus*
  • Blood Component Removal / methods*
  • COVID-19
  • Coronavirus Infections / therapy*
  • Cytokines / metabolism
  • Female
  • Granulocytes*
  • Humans
  • Male
  • Monocytes*
  • Neutrophils
  • Pandemics
  • Pneumonia, Viral / therapy*
  • SARS-CoV-2
  • Treatment Outcome

Substances

  • Cytokines